Previous close | 51.65 |
Open | 51.65 |
Bid | 51.68 x 100 |
Ask | 51.82 x 200 |
Day's range | 51.14 - 51.83 |
52-week range | 50.27 - 75.74 |
Volume | |
Avg. volume | 1,756,574 |
Market cap | 11.617B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 19.52 |
EPS (TTM) | 2.65 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 74.29 |
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.